An anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use of the same. Further, provided are a chimeric antibody comprising a CDR of the anti-CD27 antibody, a humanized antibody, a pharmaceutical composition comprising a human anti-CD27 antibody or an antigen-binding fragment thereof, and a use of the same as an anti-cancer drug. The present invention particularly relates to a human anti-CD27 antibody and a use thereof in preparing a drug for treating a CD27-mediated disease or disorder.
